Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Recurrent Clostridium Difficile Infection
NCT02686645Phase 3Unknown
- Sponsor
- Queen Elizabeth II Health Sciences Centre
- Start
- Dec 2016
- Primary completion
- Dec 2021
- Modality
- Live Biotherapeutic Products
01
Overview
Phase 3, open-label, single-arm trial of Fecal Microbiota Transplantation Capsule in Clostridium difficile infection (CDI), sponsored by Queen Elizabeth II Health Sciences Centre. Primary endpoint: Resolution of Clostridium Difficile Infection at 30 days. Status: unknown.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT02686645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686645.